Press Releases

 Sign up for email alerts here

 

Date Title and Summary Additional Formats
Toggle Summary Genocea funding highlights growing investor interest
Genocea Biosciences Inc., a Cambridge-based developer of T cell-based vaccines, took in a venture capital round worth $35 million in January. The size of the deal is one signal of increasing investor confidence in the vaccines industry at a time when pharmaceutical companies are seeing dwindling
View HTML
Toggle Summary Results from Genocea Pneumococcus Vaccine Collaboration with Children’s Hospital of Boston and PATH Published in Cell Host & Microbe View HTML
Toggle Summary Genocea Biosciences Announces Promotion of Chip Clark to President and Chief Executive Officer View HTML
Toggle Summary Genocea Biosciences Closes $35 Million Series B Financing View HTML